We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$21M
(+22%)
Cap. Flow
+$284M
Cap. Flow
% of AUM
244.1%
Top 10 Holdings %
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
+$4.59M |
| 2 |
Biogen
BIIB
|
+$3.56M |
| 3 |
Cal-Maine
CALM
|
+$2.79M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$2.48M |
| 5 |
Apple
AAPL
|
+$2.33M |
Top Sells
| 1 |
Baxter International
BAX
|
+$4.11M |
| 2 |
Gilead Sciences
GILD
|
+$2M |
| 3 |
IBM
IBM
|
+$1.48M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$930K |
| 5 |
Expedia Group
EXPE
|
+$914K |
Sector Composition
| 1 | Healthcare | 41.4% |
| 2 | Technology | 6.27% |
| 3 | Consumer Staples | 4.14% |
| 4 | Consumer Discretionary | 2.26% |
| 5 | Materials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Home Depot
HD
$338B
| $447K | 0.38% |
+3,500
| New | +$463K |
|
|
ALR
52
PUT
DELISTED
Alere Inc
ALR
| $442K | 0.38% |
50,200
| – | – |
|
53
Coca-Cola Europacific Partners
CCEP
$46.5B
| $432K | 0.37% |
+12,104
| New | +$570K |
|
54
Macy's
M
$6.23B
| $420K | 0.36% |
12,500
+5,000
| +67% | +$179K |
|
55
CALL
Regeneron Pharmaceuticals
REGN
$70.9B
| $418K | 0.36% |
25,500
+12,000
| +89% | +$4.62M |
|
|
56
Gilead Sciences
GILD
$167B
| $408K | 0.35% |
4,890
-22,500
| -82% | -$2M |
|
57
CALL
Humana
HUM
$48B
| $399K | 0.34% |
29,000
+10,000
| +53% | +$1.78M |
|
58
CALL
AT&T
T
$152B
| $399K | 0.34% |
178,740
-99,565
| -36% | -$2.96M |
|
|
59
PUT
Gilead Sciences
GILD
$167B
| $387K | 0.33% |
154,200
-119,800
| -44% | -$10.6M |
|
60
Autohome
ATHM
$2.48B
| $382K | 0.33% |
+19,015
| New | +$509K |
|
61
iShares China Large-Cap ETF
FXI
$4.6B
| $380K | 0.33% |
+11,100
| New | +$369K |
|
62
Adobe
ADBE
$94.3B
| $372K | 0.32% |
+3,882
| New | +$373K |
|
|
NBRV
63
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $372K | 0.32% |
198
+105
| +113% | +$212K |
|
|
TSRO
64
CALL
DELISTED
TESARO, Inc.
TSRO
| $371K | 0.32% |
+32,000
| New | +$1.43M |
|
|
K
65
CALL
DELISTED
Kellanova
K
| $366K | 0.31% |
87,330
-60,705
| -41% | -$4.36M |
|
66
CALL
Intuitive Surgical
ISRG
$122B
| $360K | 0.31% |
94,500
+4,500
| +5% | +$317K |
|
|
CXRX
67
PUT
DELISTED
Concordia International Corp. Common Stock
CXRX
| $348K | 0.3% |
+17,500
| New | +$461K |
|
68
SCYNEXIS
SCYX
$42.4M
| $338K | 0.29% |
1,949
+1,260
| +183% | +$356K |
|
|
GWPH
69
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $338K | 0.29% |
45,500
+15,600
| +52% | +$1.31M |
|
|
RLYP
70
CALL
DELISTED
RELYPSA INC COM
RLYP
| $334K | 0.29% |
167,000
-8,100
| -5% | -$142K |
|
71
PUT
Amgen
AMGN
$198B
| $328K | 0.28% |
55,000
+18,100
| +49% | +$2.81M |
|
|
CAB
72
DELISTED
Cabela's Inc
CAB
| $325K | 0.28% |
+6,500
| New | +$324K |
|
73
CALL
Mattel
MAT
$4.16B
| $323K | 0.28% |
50,000
| – | – |
|
|
ENDP
74
DELISTED
Endo International plc
ENDP
| $316K | 0.27% |
+20,300
| New | +$421K |
|
|
WWAV
75
CALL
DELISTED
The WhiteWave Foods Company
WWAV
| $312K | 0.27% |
84,100
-16,400
| -16% | -$704K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q2 2016 Portfolio in Review
As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.
- FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
- FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
- FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
- FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
- FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
- FT Options opened 171 new positions and closed 122 in Q2 2016.
- FT Options's portfolio value rose 22% quarter-over-quarter to $116M.
Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.